Gameto, an Austin, TX-based clinical-stage biotechnology firm growing stem cell-derived therapies for reproductive well being, raised $44M in Collection C funding.
The spherical was led by Overwater Ventures, with participation from Perception Companions, RA Capital, Two Sigma Ventures, BOLD Capital Companions, Future Ventures, Ingeborg Investments, Arcadia Funding Companions, PAGS Group, Pontiva Healthcare Companions, Portfolia, and extra buyers.
The corporate intends to make use of the funds to increase operations and its R&D efforts.
Based by Dr. Dina Radenkovic, Gameto is a well being biotechnology firm advancing packages from a cell engineering platform developed with George Church’s lab at Harvard Medical Faculty. Its lead program, Fertilo, is presently in Section 3 medical trials.
Fertilo can be the primary induced pluripotent stem cell (iPSC)-derived remedy to achieve late-stage medical growth in america. Gameto’s novel expertise is bettering reproductive care, with alternatives to shift the paradigm from IVF and egg freezing to ovarian therapeutics and delaying menopause. It’s already cleared to commercialize many ex-U.S. jurisdictions and is presently utilized in clinics in Peru, Mexicoand Australia, with extra clearances in Japan, India, Singapore, Guatemala, Argentina, Dominican Republic, and Paraguay.
Past Fertilo, Gameto is growing therapies for menopause by its Ameno program, which just lately acquired funding from the Superior Analysis Tasks Company for Well being (ARPA-H) as a part of the White Home Initiative on Ladies’s Well being Analysis. This system contains each an implantable cell remedy designed to revive ovarian hormone manufacturing and a next-generation vaginal ring enabling cyclical hormone launch patterns that extra carefully approximate pure physiology, and the corporate is hoping to deliver the vaginal ring to Section 1 medical trials within the close to future.
The financing introduced Gameto’s complete capital raised to $127M.
FinSMEs
12/08/2025
